文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

应用小型猪模型鉴定 CLN2 脑纹状体病的磁共振脑容量生物标志物。

Magnetic resonance brain volumetry biomarkers of CLN2 Batten disease identified with miniswine model.

机构信息

Department of Radiology, University of Iowa, 200 Hawkins Drive cc704 GH, Iowa City, IA, 52242, USA.

Department of Biomedical Engineering, University of Iowa, Iowa City, IA, USA.

出版信息

Sci Rep. 2023 Mar 29;13(1):5146. doi: 10.1038/s41598-023-32071-z.


DOI:10.1038/s41598-023-32071-z
PMID:36991106
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10060411/
Abstract

Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease (Batten disease) is a rare pediatric disease, with symptom development leading to clinical diagnosis. Early diagnosis and effective tracking of disease progression are required for treatment. We hypothesize that brain volumetry is valuable in identifying CLN2 disease at an early stage and tracking disease progression in a genetically modified miniswine model. CLN2 miniswine and wild type controls were evaluated at 12- and 17-months of age, correlating to early and late stages of disease progression. Magnetic resonance imaging (MRI) T1- and T2-weighted data were acquired. Total intercranial, gray matter, cerebrospinal fluid, white matter, caudate, putamen, and ventricle volumes were calculated and expressed as proportions of the intracranial volume. The brain regions were compared between timepoints and cohorts using Gardner-Altman plots, mean differences, and confidence intervals. At an early stage of disease, the total intracranial volume (- 9.06 cm), gray matter (- 4.37% 95 CI - 7.41; - 1.83), caudate (- 0.16%, 95 CI - 0.24; - 0.08) and putamen (- 0.11% 95 CI - 0.23; - 0.02) were all notably smaller in CLN2 miniswines versus WT, while cerebrospinal fluid was larger (+ 3.42%, 95 CI 2.54; 6.18). As the disease progressed to a later stage, the difference between the gray matter (- 8.27%, 95 CI - 10.1; - 5.56) and cerebrospinal fluid (+ 6.88%, 95 CI 4.31; 8.51) continued to become more pronounced, while others remained stable. MRI brain volumetry in this miniswine model of CLN2 disease is sensitive to early disease detection and longitudinal change monitoring, providing a valuable tool for pre-clinical treatment development and evaluation.

摘要

晚婴型神经元蜡样脂褐质沉积症 2 型(CLN2)病(Batten 病)是一种罕见的儿科疾病,其症状发展导致临床诊断。需要早期诊断和有效跟踪疾病进展以进行治疗。我们假设脑容积测量在早期识别 CLN2 病和跟踪遗传修饰小型猪模型中的疾病进展方面具有价值。在 12 个月和 17 个月大时评估 CLN2 小型猪和野生型对照,分别对应疾病进展的早期和晚期。采集磁共振成像(MRI)T1-和 T2 加权数据。计算总颅内、灰质、脑脊液、白质、尾状核、壳核和脑室体积,并表示为颅内体积的比例。使用 Gardner-Altman 图、均值差异和置信区间比较脑区在时间点和队列之间的差异。在疾病的早期阶段,总颅内体积(-9.06cm)、灰质(-4.37%,95%置信区间-7.41;-1.83)、尾状核(-0.16%,95%置信区间-0.24;-0.08)和壳核(-0.11%,95%置信区间-0.23;-0.02)在 CLN2 小型猪中均显著小于 WT,而脑脊液更大(+3.42%,95%置信区间 2.54;6.18)。随着疾病进展到晚期,灰质(-8.27%,95%置信区间-10.1;-5.56)和脑脊液(+6.88%,95%置信区间 4.31;8.51)之间的差异继续变得更加明显,而其他差异则保持稳定。CLN2 病小型猪模型中的 MRI 脑容积测量对早期疾病检测和纵向变化监测敏感,为临床前治疗开发和评估提供了有价值的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/b580396eb94f/41598_2023_32071_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/843b0a590993/41598_2023_32071_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/ccad78a6e9e2/41598_2023_32071_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/39ddc33818ff/41598_2023_32071_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/e187a2a6ceef/41598_2023_32071_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/02662e8b7d50/41598_2023_32071_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/bc48678a82f7/41598_2023_32071_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/b580396eb94f/41598_2023_32071_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/843b0a590993/41598_2023_32071_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/ccad78a6e9e2/41598_2023_32071_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/39ddc33818ff/41598_2023_32071_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/e187a2a6ceef/41598_2023_32071_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/02662e8b7d50/41598_2023_32071_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/bc48678a82f7/41598_2023_32071_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3dc/10060411/b580396eb94f/41598_2023_32071_Fig7_HTML.jpg

相似文献

[1]
Magnetic resonance brain volumetry biomarkers of CLN2 Batten disease identified with miniswine model.

Sci Rep. 2023-3-29

[2]
A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes.

Neurotherapeutics. 2022-10

[3]
Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).

J Neurosci Res. 2014-11

[4]
Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease).

Sci Rep. 2018-10-15

[5]
Quantitative t2 measurements in juvenile and late infantile neuronal ceroid lipofuscinosis.

Clin Neuroradiol. 2012-12-23

[6]
Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis.

Mol Genet Metab. 2015-2

[7]
Cynomolgus macaque model of neuronal ceroid lipofuscinosis type 2 disease.

Exp Neurol. 2023-5

[8]
A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies.

PLoS One. 2017-5-2

[9]
R208X mutation in CLN2 gene associated with reduced cerebrospinal fluid pterins in a girl with classic late infantile neuronal ceroid lipofuscinosis.

Croat Med J. 2003-8

[10]
Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing .

Sci Transl Med. 2020-12-2

引用本文的文献

[1]
A Case for Automated Segmentation of MRI Data in Neurodegenerative Diseases: Type II GM1 Gangliosidosis.

NeuroSci. 2025-4-3

[2]
Enzyme Replacement Therapy for CLN2 Disease: MRI Volumetry Shows Significantly Slower Volume Loss Compared with a Natural History Cohort.

AJNR Am J Neuroradiol. 2024-11-7

本文引用的文献

[1]
A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes.

Neurotherapeutics. 2022-10

[2]
Elastic mucus strands impair mucociliary clearance in cystic fibrosis pigs.

Proc Natl Acad Sci U S A. 2022-3-29

[3]
Employing Novel Porcine Models of Subcutaneous Pancreatic Cancer to Evaluate Oncological Therapies.

Methods Mol Biol. 2022

[4]
Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma.

Mol Cancer Ther. 2022-4-1

[5]
Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and Mutant Porcine Models Reveals Overlooked Challenges in Precision Modeling of Human Diseases.

Front Genet. 2021-9-23

[6]
The advancements, challenges, and future implications of the CRISPR/Cas9 system in swine research.

J Genet Genomics. 2021-5-20

[7]
MRI brain templates of the male Yucatan minipig.

Neuroimage. 2021-7-15

[8]
Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.

Int J Mol Sci. 2021-2-16

[9]
A decade of experience with genetically tailored pig models for diabetes and metabolic research.

Anim Reprod. 2020-8-26

[10]
AAV9 Gene Therapy Increases Lifespan and Treats Pathological and Behavioral Abnormalities in a Mouse Model of CLN8-Batten Disease.

Mol Ther. 2021-1-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索